Life Science Compliance Update

September

2018

A New Round of Efforts to Reform 340b: Part I, Program Transparency

Written by , Posted in Uncategorized

By Gwendolyn Ball

Ever since the creation of the 340B discount program, it has been plagued by transparency issues. Current efforts to curb pharmaceutical prices have only served to resurface these unresolved issues. This article, the first of two parts, will explore the latest developments to address 340B transparency.


   or   

  • Return to September 2018 LSC Update Table of Contents
  • Copy abstract URL
  • Order Reprints
  • Topic tags:

    June

    2018

    Maryland Loses Rx Price Gouging Law But Not The Debate

    Written by , Posted in Uncategorized

    Nicodemo (Nico) Fiorentino, Esq.

    Recently the United States Court of Appeals for the Fourth Circuit overturned Maryland’s law prohibiting price gouging for essential off–patent or generic drugs. This article highlights Maryland’s first-in-the-nation prescription drug price gouging legislation, key points to the commerce clause, and the impact the court’s ruling has on similarly proposed legislation throughout the country.


       or   

    Topic tags:

    April

    2018

    The Day After Tomorrow – The Drug Pricing Transparency Chorus Grows Louder

    Written by , Posted in Uncategorized

    Nicodemo Fiorentino, Esq. and Seth B. Whitelaw, J.D., LL.M., S.J.D.

    Drug pricing transparency, as a concept at least, is here to stay. However, the details of what that means and the new obligations that pharmaceutical companies will need to deal with are yet to be determined. For pharmaceutical compliance professionals, 2018 will continue to be a time of high uncertainty and an ever-increasing workload. This article examines the current state and what the future may hold.


       or   

    Topic tags:

    Menu Title